Tredegar Corporation (TG) News

Tredegar Corporation (TG): $14.19

-0.64 (-4.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter TG News Items

TG News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TG News Highlights

  • 500 - Internal server error
  • Over the past 8 days, the trend for TG's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • PAY are the most mentioned tickers in articles about TG.

Latest TG News From Around the Web

Below are the latest news stories about Tredegar Corp that investors may wish to consider to help them evaluate TG as an investment opportunity.

Tredegar Corporation (NYSE:TG) Goes Ex-Dividend Soon

Readers hoping to buy Tredegar Corporation ( NYSE:TG ) for its dividend will need to make their move shortly, as the...

Yahoo | June 12, 2021

Tredegar (NYSE:TG) Is Due To Pay A Dividend Of US$0.12

The board of Tredegar Corporation ( NYSE:TG ) has announced that it will pay a dividend on the 1st of July, with...

Yahoo | June 4, 2021

Tredegar Board Declares Quarterly Dividend

Tredegar Board Declares Quarterly Dividend

Yahoo | May 6, 2021

Calculating The Intrinsic Value Of Tredegar Corporation (NYSE:TG)

In this article we are going to estimate the intrinsic value of Tredegar Corporation ( NYSE:TG ) by taking the expected...

Yahoo | May 6, 2021

TG Therapeutics And Samsung Biologics Expand Ublituximab Manufacturing

Commercial-stage biopharmaceutical company TG Therapeutics and Samsung Biologics are expanding a large-scale manufacturing contract for the former’s ublituximab, an investigational monoclonal antibody. TG Therapeutics (TGTX) has submitted a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval for the combination of ublituximab and umbralisib in treating patients with chronic lymphocytic leukemia (CLL). Furthermore, TG Therapeutics is also in the process of preparing a BLA for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS). TG Therapeutics Executive Chairman and CEO Michael S.

Kailas Salunkhe on TipRanks | April 26, 2021

TSLOTS Aluminum Framing System is Expanding Operations

TSLOTS Framing System is Expanding Operations

Yahoo | March 4, 2021

CORRECTING and REPLACING Tredegar Board Declares Dividend

Tredegar Board Declares Quarterly Dividend

Yahoo | February 25, 2021

New 200-place Welsh school planned for Tredegar enters phase two

Extra school places could be created as part of the primary in Blaenau Gwent

Wales Online | February 24, 2021

TG’s Ukoniq Gets FDA Nod For Lymphoma Therapies; Shares Pop 12%

Shares of TG Therapeutics spiked 12% on Feb. 5 after the US Food and Drug Administration (FDA) approved Ukoniq (umbralisib), its investigational compound, for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL). The stock gained another 4% in Friday's after-hours trading. Specifically, the FDA granted approval for the treatment of Ukoniq in MZL patients who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. TG Therapeutics (TGTX) is a biopharma company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

Sharon Wrobel on TipRanks | February 7, 2021

Herefordshire sawmill fined after Tredegar worker crushed and killed by machine

A SAWMILL in Herefordshire has been fined £200,000 after a man was crushed and killed while at work there three years ago.

South Wales Argus | February 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.7956 seconds.